Thierry Gustot, François Durand, Didier Lebrec, Jean‐Louis Vincent, Richard Moreau – 20 November 2009 – Sepsis is physiologically viewed as a proinflammatory and procoagulant response to invading pathogens. There are three recognized stages in the inflammatory response with progressively increased risk of end‐organ failure and death: sepsis, severe sepsis, and septic shock. Patients with cirrhosis are prone to develop sepsis, sepsis‐induced organ failure, and death.
Montserrat Moreno, Javier F. Chaves, Pau Sancho‐Bru, Fernando Ramalho, Leandra N. Ramalho, Maria L. Mansego, Carmen Ivorra, Marlene Dominguez, Laura Conde, Cristina Millán, Montserrat Marí, Jordi Colmenero, Juan J. Lozano, Pedro Jares, Josep Vidal, Xavier Forns, Vicente Arroyo, Juan Caballería, Pere Ginès, Ramón Bataller – 9 November 2009 – There are no effective antifibrotic therapies for patients with liver diseases. We performed an experimental and translational study to investigate whether ghrelin, an orexigenic hormone with pleiotropic properties, modulates liver fibrogenesis.
Laurent Castéra, Juliette Foucher, Pierre‐Henri Bernard, Françoise Carvalho, Daniele Allaix, Wassil Merrouche, Patrice Couzigou, Victor de Lédinghen – 9 November 2009 – Liver stiffness measurement (LSM) based on transient elastography (TE, FibroScan) is gaining in popularity for noninvasive assessment of liver fibrosis. However, LSM has limitations, which have not yet been thoroughly evaluated. We prospectively investigated the frequency and determinants of LSM failure and unreliable results over a 5‐year period, based on 13,369 examinations (134,239 shots).
Montserrat Moreno, Teresa Gonzalo, Robbert J. Kok, Pau Sancho‐Bru, Marike van Beuge, Josine Swart, Jai Prakash, Kai Temming, Constantino Fondevila, Leonie Beljaars, Marie Lacombe, Paul van der Hoeven, Vicente Arroyo, Klaas Poelstra, David A. Brenner, Pere Ginès, Ramón Bataller – 9 November 2009 – There is no effective therapy for advanced liver fibrosis. Angiotensin type 1 (AT1) receptor blockers attenuate liver fibrogenesis, yet their efficacy in reversing advanced fibrosis is unknown.
Hisashi Moriguchi, Raymond T. Chung, Chifumi Sato – 9 November 2009
Narci C. Teoh, Jacqueline Williams, Jennifer Hartley, Jun Yu, Robert S. McCuskey, Geoffrey C. Farrell – 9 November 2009 – Steatosis increases operative morbidity/mortality from ischemia–reperfusion injury (IRI); few pharmacological approaches have been protective.
Anna Alisi, Clara Balsano – 3 November 2009
D. Montgomery Bissell – 29 October 2009 – D. Montgomery Bissell briefly describes the way he came to a career in academic medicine, how he found mentors, initial projects, and finally a focus on matrix biology and hepatic fibrosis. He draws some lessons from the experience, which should have relevance for physician‐scientist trainees, those considering that path, anyone with responsibility for training the next generation, institutional leaders, and the National Institutes of Health. (HEPATOLOGY 2009;50:1330–1338.)
Gianluigi Giannelli – 29 October 2009
Ling Xiao Liu, Nikki P. Lee, Vivian W. Chan, Wen Xue, Lars Zender, Chunsheng Zhang, Mao Mao, Hongyue Dai, Xiao Lin Wang, Michelle Z. Xu, Terence K. Lee, Irene O. Ng, Yangchao Chen, Hsiang‐fu Kung, Scott W. Lowe, Ronnie T.P. Poon, Jian Hua Wang, John M. Luk – 29 October 2009 – Hepatocellular carcinoma (HCC) is a lethal malignancy for which there are no effective therapies. To develop rational therapeutic approaches for treating this disease, we are performing proof‐of‐principle studies targeting molecules crucial for the development of HCC.